227 related articles for article (PubMed ID: 19141642)
21. Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib.
Wahl K; Siegemund M; Lehner F; Vondran F; Nüssler A; Länger F; Krech T; Kontermann R; Manns MP; Schulze-Osthoff K; Pfizenmaier K; Bantel H
Hepatology; 2013 Feb; 57(2):625-36. PubMed ID: 22991197
[TBL] [Abstract][Full Text] [Related]
22. Knock down of p53 levels in human keratinocytes increases susceptibility to type I and type II interferon-induced apoptosis mediated by a TRAIL dependent pathway.
Chaturvedi V; Bodner B; Qin JZ; Nickoloff BJ
J Dermatol Sci; 2006 Jan; 41(1):31-41. PubMed ID: 16289694
[TBL] [Abstract][Full Text] [Related]
23. Adenoviral-mediated transfer of p53 gene enhances TRAIL-induced apoptosis in human hepatocellular carcinoma cells.
Inoue H; Shiraki K; Murata K; Sugimoto K; Kawakita T; Yamaguchi Y; Saitou Y; Enokimura N; Yamamoto N; Yamanaka Y; Nakano T
Int J Mol Med; 2004 Aug; 14(2):271-5. PubMed ID: 15254777
[TBL] [Abstract][Full Text] [Related]
24. Galectin-1 Modulates the Survival and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Sensitivity in Human Hepatocellular Carcinoma Cells.
Li J; Sun RR; Yu ZJ; Liang H; Shen S; Kan Q
Cancer Biother Radiopharm; 2015 Oct; 30(8):336-41. PubMed ID: 26348206
[TBL] [Abstract][Full Text] [Related]
25. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL.
Pathil A; Armeanu S; Venturelli S; Mascagni P; Weiss TS; Gregor M; Lauer UM; Bitzer M
Hepatology; 2006 Mar; 43(3):425-34. PubMed ID: 16583461
[TBL] [Abstract][Full Text] [Related]
26. [Newcastle disease virus enhances tumoricidal activity of mouse NK cells against mouse Novikoff hepatoma cells via up-regulating expression of TRAIL on the NK cells].
Song D; Liang Y; Fan X; Yin J; Gong J; Lai Z; Gao L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 May; 31(5):599-604. PubMed ID: 25940284
[TBL] [Abstract][Full Text] [Related]
27. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
[TBL] [Abstract][Full Text] [Related]
28. JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand.
Mucha SR; Rizzani A; Gerbes AL; Camaj P; Thasler WE; Bruns CJ; Eichhorst ST; Gallmeier E; Kolligs FT; Göke B; De Toni EN
Gut; 2009 May; 58(5):688-98. PubMed ID: 19106147
[TBL] [Abstract][Full Text] [Related]
29. miR-370 regulates ISG15 expression and influences IFN-α sensitivity in hepatocellular carcinoma cells.
Liu Z; Ma M; Yan L; Chen S; Li S; Yang D; Wang X; Xiao H; Deng H; Zhu H; Zuo C; Xia M
Cancer Biomark; 2018; 22(3):453-466. PubMed ID: 29758929
[TBL] [Abstract][Full Text] [Related]
30. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
[TBL] [Abstract][Full Text] [Related]
31. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.
Ganten TM; Koschny R; Haas TL; Sykora J; Li-Weber M; Herzer K; Walczak H
Hepatology; 2005 Sep; 42(3):588-97. PubMed ID: 16037944
[TBL] [Abstract][Full Text] [Related]
32. Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma.
Zhang X; Yang XR; Sun C; Hu B; Sun YF; Huang XW; Wang Z; He YF; Zeng HY; Qiu SJ; Cao Y; Fan J; Zhou J
Cancer Lett; 2015 Sep; 366(1):112-22. PubMed ID: 26118777
[TBL] [Abstract][Full Text] [Related]
33. Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPS down-regulation.
Kim JY; Kim EH; Park SS; Lim JH; Kwon TK; Choi KS
J Cell Biochem; 2008 Dec; 105(6):1386-98. PubMed ID: 18980244
[TBL] [Abstract][Full Text] [Related]
34. The key role of PML in IFN-α induced cellular senescence of human mesenchymal stromal cells.
Fu S; Wei J; Wang G; Wang B; Wang Y; Lai X; Huang H
Int J Oncol; 2015 Jan; 46(1):351-9. PubMed ID: 25354534
[TBL] [Abstract][Full Text] [Related]
35. 5, 7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells.
Yang JF; Cao JG; Tian L; Liu F
Cancer Chemother Pharmacol; 2012 Jan; 69(1):195-206. PubMed ID: 21660448
[TBL] [Abstract][Full Text] [Related]
36. Interferons alpha and gamma induce p53-dependent and p53-independent apoptosis, respectively.
Porta C; Hadj-Slimane R; Nejmeddine M; Pampin M; Tovey MG; Espert L; Alvarez S; Chelbi-Alix MK
Oncogene; 2005 Jan; 24(4):605-15. PubMed ID: 15580300
[TBL] [Abstract][Full Text] [Related]
37. Knocking down PML impairs p53 signaling transduction pathway and suppresses irradiation induced apoptosis in breast carcinoma cell MCF-7.
Bao-Lei T; Zhu-Zhong M; Yi S; Jun-Jie Q; Yan D; Hua L; Bin L; Guo-Wei Z; Zhi-Xian S
J Cell Biochem; 2006 Feb; 97(3):561-71. PubMed ID: 16215989
[TBL] [Abstract][Full Text] [Related]
38. DNMT1 and DNMT3b silencing sensitizes human hepatoma cells to TRAIL-mediated apoptosis via up-regulation of TRAIL-R2/DR5 and caspase-8.
Kurita S; Higuchi H; Saito Y; Nakamoto N; Takaishi H; Tada S; Saito H; Gores GJ; Hibi T
Cancer Sci; 2010 Jun; 101(6):1431-9. PubMed ID: 20398055
[TBL] [Abstract][Full Text] [Related]
39. Concordant expression of proto-oncogene promyelocytic leukemia and major histocompatibility antigen HLA class I in human hepatocellular carcinoma.
Xia M; Zhang JQ; Shen YQ; Xu LH; Chen AQ; Miao FQ; Xie W
Tissue Antigens; 2007 Oct; 70(4):272-82. PubMed ID: 17767548
[TBL] [Abstract][Full Text] [Related]
40. Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro.
Nakamura M; Nagano H; Sakon M; Yamamoto T; Ota H; Wada H; Damdinsuren B; Noda T; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Nakamori S; Dono K; Monden M
J Hepatol; 2007 Jan; 46(1):77-88. PubMed ID: 17045692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
